88 molecules in the GLP-1 and incretin landscape.
Compare trial volume, geographic footprint and measured outcomes across named molecules.
88 named molecules; 312 trials without a named molecule remain in Atlas totals. Source: ClinicalTrials.gov, as of July 6, 2026.
88 of 88
Oral / Subcutaneous · GLP-1 agonist
Semaglutide
12,451 endpoints measured
725
Trials
348
Ongoing48%
7,428
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 agonist
Liraglutide
8,104 endpoints measured
518
Trials
46
Ongoing9%
3,600
Sites
Endpoint mix
Relative within each asset
Intravenous / Subcutaneous · GLP-1 agonist
Exenatide
3,043 endpoints measured
387
Trials
21
Ongoing5%
3,307
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 / GIP dual
Tirzepatide
3,532 endpoints measured
265
Trials
179
Ongoing68%
3,046
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 agonist
Dulaglutide
2,251 endpoints measured
140
Trials
29
Ongoing21%
2,415
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 agonist
Lixisenatide
906 endpoints measured
79
Trials
9
Ongoing11%
2,091
Sites
Endpoint mix
Relative within each asset
Intravenous / Subcutaneous · Amylin analog
Pramlintide
498 endpoints measured
64
Trials
5
Ongoing8%
271
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 / amylin
CagriSema / cagrilintide
1,049 endpoints measured
52
Trials
22
Ongoing42%
1,915
Sites
Endpoint mix
Relative within each asset
Oral · GLP-1 agonist
Orforglipron
476 endpoints measured
49
Trials
17
Ongoing35%
1,691
Sites
Endpoint mix
Relative within each asset
Avexitide
0 endpoints measured
45
Trials
8
Ongoing18%
55
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 agonist
Albiglutide
530 endpoints measured
41
Trials
3
Ongoing7%
1,396
Sites
Endpoint mix
Relative within each asset
Oral / Subcutaneous · GLP-1 / GIP dual
HRS9531
480 endpoints measured
38
Trials
21
Ongoing55%
169
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 / glucagon dual
Mazdutide
477 endpoints measured
37
Trials
21
Ongoing57%
146
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 / GIP / glucagon triple
Retatrutide
308 endpoints measured
34
Trials
15
Ongoing44%
1,572
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 / glucagon dual
Survodutide
330 endpoints measured
31
Trials
9
Ongoing29%
1,314
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 agonist / GIP antagonist
Maridebart cafraglutide / MariTide
438 endpoints measured
27
Trials
17
Ongoing63%
1,522
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 agonist
GZR18
217 endpoints measured
26
Trials
18
Ongoing69%
38
Sites
Endpoint mix
Relative within each asset
Subcutaneous · GLP-1 / glucagon dual
Cotadutide
450 endpoints measured
24
Trials
0
Ongoing0%
341
Sites
Endpoint mix
Relative within each asset
Oral · GLP-1 agonist
KAI-7535 / HRS-7535
185 endpoints measured
22
Trials
7
Ongoing32%
40
Sites
Endpoint mix
Relative within each asset
Oral · GLP-1 / amylin
Amycretin / zenagamtide
368 endpoints measured
21
Trials
12
Ongoing57%
1,347
Sites
Endpoint mix
Relative within each asset
Oral · GLP-1 agonist
Danuglipron
402 endpoints measured
20
Trials
0
Ongoing0%
153
Sites
Endpoint mix
Relative within each asset
Subcutaneous · Amylin analog
Eloralintide
155 endpoints measured
19
Trials
13
Ongoing68%
687
Sites
Endpoint mix
Relative within each asset
Oral · GLP-1 agonist
AZD5004 / ECC5004
256 endpoints measured
16
Trials
2
Ongoing13%
155
Sites
Endpoint mix
Relative within each asset
Oral / Subcutaneous · GLP-1 / GIP dual
BGM0504
91 endpoints measured
15
Trials
10
Ongoing67%
10
Sites
Endpoint mix
Relative within each asset
Showing 1-24 of 88 assets